Biosyent Inc (BIOYF) 6.3900 $BIOYF CORRECTION FROM

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biosyent Inc (BIOYF) 6.3900 $BIOYF

CORRECTION FROM SOURCE: BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
Marketwired - Wed May 13, 3:22PM CDT
A correction from source is being issued with respect to the BioSyent Inc. release that was disseminated May 13, 2015 at 08:00 ET. The third bullet point previously compared Q1 2015 with Q1 2013 as opposed to Q1 2014. The correct version follows:
RX.VN: 7.570 (-0.250)

BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
Marketwired - Wed May 13, 7:02AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its First Quarter (Q1 2015) financial results. Key highlights include:
RX.VN: 7.570 (-0.250)

BioSyent to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference
Marketwired - Fri May 01, 3:02PM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the 2015 Bloom Burton & Co. Healthcare Investor Conference at 9:30am (ET), May 5, 2015 at the Sheraton Centre Toronto Hotel, Toronto, Canada. Mr. Goehrum will provide an overview of the Company and its corporate activities.
RX.VN: 7.570 (-0.250)

BioSyent Comments on Recent Market Activity
Marketwired - Fri Apr 10, 7:01AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) wishes to comment on the unusual recent market activity in its stock. The Company advises that it is not aware of any material undisclosed business development that should account for the decrease in its stock price on Thursday, April 9, 2015. The Company looks forward to disclosing its first quarter results on May 13, 2015.
RX.VN: 7.570 (-0.250)

BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System(R)
Marketwired - Tue Feb 03, 7:05AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of the Aguettant System(R) for pre-filled syringes (PFS), a new urgent care product for use in hospitals and acute care settings.
RX.VN: 7.570 (-0.250)

BioSyent Pharma Launches New Proktis-M(R) Suppositories
Marketwired - Mon Nov 24, 7:07AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M(R) suppositories.
RX.VN: 7.570 (-0.250)

BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%
Marketwired - Mon Oct 20, 7:06AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its Third Quarter (Q3 2014) and nine months financial results for the three and nine months ending September 30, 2014. Key highlights include:
RX.VN: 7.570 (-0.250)

BioSyent Releases Q2 and Six Month Results-Q2 Sales Increase 72%, Net Income After Tax Up 112%
Marketwire - Thu Aug 21, 7:03AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its Second Quarter (Q2 2014) and first half (H1 2014) financial results for the three and six months ending June 30, 2014. Key highlights include:
RX.VN: 7.570 (-0.250)

BioSyent Pharma Signs Exclusive Licensing and Distribution Agreement For New Urgent Care Drug Product
Marketwire - Wed Jul 23, 8:44AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Licensing and Distribution Agreement with an existing European partner for a new product that will be marketed by its' Hospital Products Division. The new product utilizes a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies. The product will be launched after Health Canada approval.
RX.VN: 7.570 (-0.250)

BioSyent Inc. (TSXV:RX) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com
Thomson Reuters ONE - Mon Jul 07, 6:28PM CDT
Vancouver, BC, July 7, 2014 - Toronto based eResearch has issued a StockPotentials report on BioSyent Inc. (TSXV:RX), a Toronto-based, growth oriented, independent pharmaceutical company. StockPotentials reports cover smaller companies eResearch believes would be primarily of interest to retail investors.
RX.VN: 7.570 (-0.250)

eResearch Issues Stock Potentials Report on BioSyent Inc.
ACCESSWIRE - Thu Jul 03, 10:51AM CDT
Toronto, ON / ACCESSWIRE / July 3, 2014 / eResearch Corporation provides Stock Potentials reports to highlight interesting prospects which may benefit from the exposure that eResearch can provide through its extensive electronic distribution network. This latest report features BioSyent Inc., a growth-oriented specialty pharmaceutical company, based in Toronto.
RX.VN: 7.570 (-0.250)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China, Europe, Africa Team Up for Green Energy Push

Updated Category News Views 128

The Need for Unity in a Warming World Some folks out there might be scratching their heads, wondering what sparks are flying between China, Europe, and Africa this time. Well, during the 2026 China-Europe-Africa Green Energy Development Forum held in sunny Zhejiang, the theme was loud and clear: We've got to deepen green partnerships to build a zero-carbon future. They're...

Continue Reading
Delta Marks 19 Years at COP With Bold New Initiatives

Updated Category News Views 44

Delta's Commitment to Global Sustainability Delta's name pops up yet again at the United Nations Climate Change Conference (COP31) in Antalya, Turkey, marking the company's 19th consecutive year of participation. They're mounting efforts to hit that "35×35" target, aiming for 35% electrification by 2035. This isn't just fluff and rhetoric—it’s Delta taking the lead...

Continue Reading
CHARMANT Eyewear Fuses Fashion and Functionality

Updated Category News Views 8

Eyewear ain’t just about seeing clearly anymore—it’s fashion with a capital ‘F’. The CHARMANT Japanese Made brand decided to foist this idea upon the world, putting their money where your eyeballs are, by injecting a dose of trendy glam into what they already do so well: comfort. Fusion of Style and Comfort Catch this: CHARMANT hit the global stage back in June...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 322

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 199

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
Zabalafin Hydrogel: Promise in Treating Atopic Dermatitis

Updated Category News Views 20

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 172

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
Higer Buses Debut in UK: Expansion on Full Throttle

Updated Category News Views 66

Shifting Gears in the UK: Higer Enters the Fray You don't just waltz into the UK's bus and coach market without making some serious noise. Well, Higer is doing just that at Euro Bus Expo 2026. Birmingham's NEC turned into a stage for their showdown, where they unveiled three models: Azure 9, V12, and V10. The star of the show, the Azure 9, is tailored just for the Brits,...

Continue Reading
Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 149

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
Leatt Gears Up for Q3 Results Conference Call

Updated Category News Views 27

A good heads-up, folks, isn't just about keeping helmets snug—it’s about knowing when to cash in, especially when Leatt Corporation's got their Q3 results ready to drop. November 12 is the big day, so circle that on your calendars. They're rolling out the numbers before the market even gets its coffee, possibly nudging the ticker, OTCQB:LEAT, in a ripple you’ll want...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Developments from Compass Therapeutics at Upcoming Meeting

Updated Category News Views 79

Upcoming Poster Presentation Announcement Compass Therapeutics, Inc. (NASDAQ: CMPX), a pioneering clinical-stage biopharmaceutical company specializing in oncology, has announced an exciting opportunity to showcase its research at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. This event is scheduled to take place from November 8–10, 2024,...

Continue Reading
Good Times Restaurants Posts Positive Growth in Q1 2025

Updated Category News Views 186

Good Times Restaurants Reports Strong Financial Performance Good Times Restaurants Inc. (NASDAQ: GTIM), the well-known operator of popular dining brands like Bad Daddy's Burger Bar and Good Times Burgers & Frozen Custard, has released its financial results for the first quarter of the fiscal year. The company has shown robust growth, signaling a positive trend in its...

Continue Reading
Alaska Air Group Reveals Financial Outlook and Updates

Updated Category News Views 124

Alaska Air Group Provides Financial Update Today, Alaska Air Group, Inc. (NYSE: ALK), a leading American airline, revealed important information regarding its financial outlook through an official filing with the Securities and Exchange Commission (SEC). This update outlines the company’s present financial conditions and operations, providing key insights valuable to...

Continue Reading
Transforming Tool Tracking Software for Unmatched Efficiency

Updated Category News Views 184

Expanding Tool Tracking Software Market Dynamics The global tool tracking software industry is on an impressive trajectory, experiencing substantial growth. Currently valued at approximately US$ 39.02 billion, the market is expected to escalate to US$ 124.90 billion by 2033. This marks a notable compound annual growth rate (CAGR) of 13.8%, highlighting the increasing...

Continue Reading
Major Developments in Class Actions for Driven Brands and More

Updated Category News Views 200

Investigating Shareholder Claims for Driven Brands Holdings, Inc. As a long-term shareholder of Driven Brands Holdings, Inc. (NASDAQ: DRVN), you may be interested in the ongoing investigation by the Grabar Law Office. This investigation seeks answers on whether certain company officers have fulfilled their fiduciary responsibilities. If you have held your shares...

Continue Reading